1. Introduction
===============

Early mammalian development is a process that progressively alters cell plasticity as cells commit to their differentiated state. These changes in cell state are accompanied by dynamic changes in the transcriptome, chromatin properties and nuclear organization of the genome. In the early embryo, cells of the inner cell mass (ICM), and later of the epiblast, are pluripotent. These cells differentiate into cells of the three germ layers, endoderm, mesoderm, and ectoderm, which give rise to all cells of the mature organism. These cells are also capable of self-renewal, as demonstrated by embryonic stem (ES) cells and epiblast stem cells (EpiSC), which are isolated from the early embryo, are maintained in culture in the pluripotent state and can be induced to differentiate (*in vitro* or *in vivo*) into cells from each of the three germ layers \[[@B1-genes-06-00641],[@B2-genes-06-00641],[@B3-genes-06-00641]\].

Dynamic changes in the transcriptome that occur during lineage commitment and cellular reprogramming are orchestrated by *cis*-regulatory elements and *trans*-regulatory factors. The *cis*-regulatory elements (CREs) are regions that control transcription such as promoters, enhancers and insulators. While promoters are immediately upstream of the gene transcription start sites (TSS), enhancers and insulators can be located at megabase (Mb) distances from the TSS of the gene(s) they regulate. These distal CREs form chromatin loops to contact and regulate their target genes; as a result, there has been an increasing interest in understanding chromatin folding properties in different cellular contexts. CREs are sequences that function through binding of transcription factors and co-factors, the *trans*-regulatory factors (TRFs), which in turn regulate RNA polymerase association with DNA and its activity. Chromatin accessibility and transcriptional output from the genome depends on TRF availability and activity. TRFs combinatorially establish and maintain cell states, as revealed by the observation that ectopic expression of transcription factors alters cell state. Pioneered by Takahashi and Yamanaka, the cell reprogramming experimental approach involves expression of four ES cell-expressed transcription factors, *Oct4* (also known as *Pou5f1*), *Sox2*, *Klf4*, and c-*Myc* (OSKM), to reprogram somatic cells to an induced pluripotent stem (iPS) cell state \[[@B4-genes-06-00641]\].

In addition to the changes in chromatin accessibility and transcriptional output throughout lineage commitment and cellular reprogramming, interphase nuclei display a dynamic structural reorganization of their genomes. The folding patterns adopted by a cell's genome in three-dimensional nuclear space are critical for establishing cell identity and maintenance of the transcriptional program. Across cell types, differential chromosome conformations reflect a complex hierarchical compartmentalization of the genome. Chromosomes occupy largely discrete regions within the nucleus known as territories \[[@B5-genes-06-00641]\]. Individual chromosome territories are further sub-divided into Mb-sized topologically associated domains (TADs) \[[@B6-genes-06-00641]\]. TADs in turn contain contact domains less than 200 kilobases (kb) in size \[[@B7-genes-06-00641]\] and domains housing chromatin loops of various sizes. Many such chromatin loops are highly cell type-specific and allow CREs otherwise distal to one another in the linear genome to be brought into close spatial proximity to a gene TSS, an event associated with that gene's expression. While other models of enhancer function that involve either partial or no loop formation have been proposed \[[@B8-genes-06-00641]\], several genome folding studies highlight the role of chromatin loop formation in gene regulation.

Repositioning of gene loci within the nuclear space and altered configuration of entire chromosomes occur as ES cells differentiate and somatic cells undergo reprogramming. Despite these changes, some architectural features of genome organization appear to be more universal and are conserved throughout cellular differentiation. In this review, we discuss the dynamic features of chromatin and genome topology in the context of lineage commitment and cellular reprogramming and highlight emerging mechanisms controlling the concomitant changes in cellular phenotypes.

2. Transcriptional Control of Lineage Commitment and Reprogramming
==================================================================

A large number of transcription factors with lineage-specific expression patterns in the pre-implantation embryo have been identified. Many such factors are required for pluripotency and for one or more of lineage establishment, maintenance or differentiation. In the early embryo the HIPPO signaling pathway is the earliest identified signaling mechanism; this pathway requires the TEAD transcription factor family member, *Tead4*. Mouse mutants lacking *Tead4* die prior to the blastocyst stage due to a failure to form trophectoderm, which consists of cells that differentiate to extra-embryonic tissues like the placenta \[[@B9-genes-06-00641],[@B10-genes-06-00641]\]. At the same time the HIPPO pathway restricts *Sox2* expression to ICM progenitors prior to the blastocyst stage \[[@B11-genes-06-00641]\]. *Sox2* null embryos develop past the blastocyst stage but die shortly after implantation due to a failure in maintaining pluripotent epiblast cells \[[@B12-genes-06-00641]\].

The OCT4 transcription factor, which binds DNA as a dimer with SOX2 to regulate transcription, is also required for pluripotency maintenance in the early embryo \[[@B13-genes-06-00641],[@B14-genes-06-00641],[@B15-genes-06-00641]\]. *Oct4* deleted embryos die prior to implantation due to an inability to maintain pluripotency in the ICM, and cells of the ICM are instead restricted to the trophectoderm lineage \[[@B15-genes-06-00641]\]. In the mouse 8 cell embryo, fluorescence decay after photoactivation (FDAP) has been applied to determine the binding kinetics of pluripotency-associated transcription factors \[[@B16-genes-06-00641]\]. Before other morphological signs of lineage commitment can be observed, OCT4 displays slower kinetics in cells that later commit to the ICM lineage compared to those that contribute to the extra-embryonic lineage. Additionally, both OCT4 and SOX2 exhibit slower dynamics in the established ICM than in the trophectoderm \[[@B17-genes-06-00641]\].

Although not one of the original Yamanaka factors, NANOG is also involved in maintaining pluripotency through binding of CREs in conjunction with OCT4 and SOX2 \[[@B14-genes-06-00641]\]. Homozygous deletion of *Nanog* causes pre-implantation lethality in mice; in these embryos the ICM forms but loses pluripotency and later forms only parietal endoderm-like cells \[[@B18-genes-06-00641]\]. Furthermore, *Nanog* over-expression in ES cells negates the need for LIF (Leukemia Inhibitory Factor) in culture media, revealing that *Nanog* expression can maintain pluripotency in the absence of external stimuli \[[@B18-genes-06-00641]\]. In addition to their involvement in maintaining pluripotency in ES cells and in cells of the early embryo, many of these transcription factors are also required for early lineage commitment \[[@B19-genes-06-00641]\].

As previously mentioned, reprogramming somatic cells to iPS cells was first accomplished by forced expression of a cocktail of four transcription factors, OSKM. These transcription factors modify the epigenome in the somatic cell, causing genome-wide opening of chromatin, and eventually establish the transcriptome in iPS cells \[[@B20-genes-06-00641]\]. During the early stages of reprogramming, stochastic gene expression occurs in the entire cell population and only a very small subset will eventually become true iPS cells \[[@B21-genes-06-00641]\]. Select genes, such as *Esrrb* and *Dppa2*, are predictive markers for cells that are likely to progress to pluripotency. During later reprogramming stages expression of endogenous *Sox2* is highly deterministic of the few cells that will form fully reprogrammed iPS cells \[[@B21-genes-06-00641]\]. This is not the case for all reprogramming factors; expression of endogenous *Oct4* does not specifically mark cells that will go on to form iPS cells as many *Oct4*-positive cells stall at an intermediate partially differentiated stage \[[@B21-genes-06-00641]\]. Since reprogramming with OSKM is inefficient, with few cells acquiring a full iPS state, there has been significant focus on optimizing reprogramming procedures.

Multiple routes to reprogramming have been developed through transcription factor substitution or addition to the OSKM cocktail. For example, *Esrrb* can replace *Klf4,* and *Lin28* can replace c-*Myc* in the OSKM cocktail \[[@B22-genes-06-00641],[@B23-genes-06-00641]\]. Similarly, functional redundancy between members of the same protein family exists; *Klf2* and *Klf5*, both of which are expressed in ES cells, are redundant with *Klf4* in the core ES cell transcriptional circuitry \[[@B22-genes-06-00641]\]. All GATA family proteins are capable of replacing *Oct4* in reprogramming and are thought to do so by supporting expression of *Sall4*, another essential pluripotency-associated transcription factor \[[@B24-genes-06-00641]\]. Not all pluripotency factors, however, are required for reprogramming, as *Nanog* is dispensable for iPS cell generation \[[@B25-genes-06-00641]\]. *Nanog* null fibroblasts can give rise to *Nanog* null iPS cells whose transcriptome is highly similar to that of wild type iPS cells. Regardless of the cocktail of reprogramming factors used, these proteins must alter the epigenetic landscape of the differentiated cell to establish pluripotency.

3. Dynamic Chromatin Modifications
==================================

Observations of whole nuclei reveal that the chromatin landscape of ES cells is a loosely packed mesh of fibers, with less condensed chromatin than that observed in somatic cells \[[@B26-genes-06-00641]\]. Additionally, super-resolution microscopy indicates that nucleosomes are found in clusters throughout the nucleus, with ES cells having smaller and less dense clusters than differentiating cells, which reflects a more open chromatin configuration in ES cells \[[@B27-genes-06-00641]\]. In the tightly associated arrangement found in heterochromatin, histone H1 is bound at the linker DNA between nucleosomes. Euchromatic regions containing expressed genes are more loosely associated with nucleosomes and display unbound linker DNA between individual nucleosomes \[[@B28-genes-06-00641]\].

The degree to which DNA is exposed for regulation depends greatly on epigenetic modification of the histones, particularly histone H3. These modifications include acetylation (ac) and mono-, di- or tri-methylation (me1, me2, me3) of lysine residues, with functions that differ depending on the nucleosome subunit and specific residue that has been modified. Furthermore, chromatin is remodeled by proteins that slide and remove nucleosomes and create nucleosome-free regions at active gene TSS and distal CREs. A region's specific patterns of histone modifications can be diagnostic of the potential activity of that region. For example, H3K36me3 is associated with transcribed gene bodies, whereas the TSS of active genes are marked by H3K4me3 \[[@B29-genes-06-00641],[@B30-genes-06-00641],[@B31-genes-06-00641]\]. Different H3K27 methylation states denote distinct regions that do not overlap; H3K27me1 is found in intragenic transcribed regions and correlates with H3K36me3 deposition, whereas H3K27me2 is found across broad intergenic and intragenic regions \[[@B32-genes-06-00641]\]. H3K27me3 by contrast is associated with Polycomb-mediated gene repression in mammalian cells \[[@B33-genes-06-00641],[@B34-genes-06-00641]\]. H3K9me3 is associated with heterochromatic regions of the genome that, in ES cells and fully reprogrammed iPS cells, are organized in accessible 10 nm chromatin fibers similar to those in the surrounding euchromatin \[[@B35-genes-06-00641],[@B36-genes-06-00641]\]. In somatic and partially reprogrammed cells, H3K9me3-marked nucleosomes are found in tightly packed chromocentres that are not observed in ES cells \[[@B36-genes-06-00641]\]. Interestingly, in pluripotent cells, a bivalent state has been observed in which regions are modified by both H3K27me3 and H3K4me3; this state is associated with inactive, poised developmentally regulated genes that become active as the cells differentiate \[[@B36-genes-06-00641]\]. Furthermore, a group of regulatory regions distinct from poised enhancers has been identified in select differentiated cells \[[@B37-genes-06-00641]\]. Dubbed latent enhancers, these regions are bound by transcription factors and acquire active H3K4me1 and H3K27ac marks only upon cells' exposure to biochemical stimuli. Removal of said stimuli results in a concomitant depletion of H3K27ac and regulator occupancy without affecting H3K4me1 enrichment. Later re-stimulation causes a faster and stronger response at latent enhancers than that observed during the first stimulus exposure, an observation consistent with the notion of H3K4me1 retention facilitating the re-activation of these regulatory regions \[[@B37-genes-06-00641]\]. The identification of poised and latent enhancers therefore highlights the dynamic nature of histone modifications.

Changes in cell states are accompanied by profound changes in the transcriptome of the cell, which in turn arise from changes in the activity of transcriptional regulators at CREs. Studies investigating chromatin modifications in different cell types revealed that promoter modifications were more consistent across different cell types whereas distal regions displayed more dynamic cell type-specific modifications \[[@B38-genes-06-00641]\]. Some of these distal regions display enhancer activity, or position- and orientation-independent activation of transcription in reporter assays. Putative enhancers defined by ChIP-seq are nucleosome-depleted and have an array of histone marks and protein associations that appear to separate their function into distinct classes. Putative enhancer regions near transcribed genes in ES cells are marked by enrichment of both H3K4me1 \[[@B31-genes-06-00641]\] and H3K27ac \[[@B39-genes-06-00641]\], binding of chromatin modifiers p300 and BRG1 \[[@B40-genes-06-00641],[@B41-genes-06-00641]\] and binding of multiple transcription factors \[[@B14-genes-06-00641],[@B42-genes-06-00641]\]. By contrast, poised enhancers are enriched with H3K27me3, are depleted of H3K27ac and are proximal to inactive genes \[[@B41-genes-06-00641],[@B43-genes-06-00641],[@B44-genes-06-00641],[@B45-genes-06-00641]\]. Poised enhancers are thought to regulate genes required upon differentiation of ES cells, since they acquire H3K27ac during commitment to specific lineages \[[@B41-genes-06-00641],[@B43-genes-06-00641],[@B44-genes-06-00641],[@B45-genes-06-00641]\].

Ectopic expression of ES cell-specific transcription factors results in genome-wide epigenetic and transcriptional alterations, allowing cells to move back toward pluripotency \[[@B46-genes-06-00641]\]. Treated cells that reach the fully reprogrammed state of iPS cells regain their pluripotent characteristics, are capable of forming all three germ layers and can be used to generate viable mice \[[@B47-genes-06-00641]\]. The early steps of somatic cell reprogramming by expression of OSKM are characterized by depletion of global H3K27me3 \[[@B20-genes-06-00641]\], mediated by demethylases including KDM6A \[[@B48-genes-06-00641]\]; re-establishment of global H3K27me3 levels occurs as cells acquire a reprogrammed state \[[@B20-genes-06-00641]\]. In the early stages of reprogramming, promoters for genes that are expressed later in reprogramming are marked by enhanced H3K4me2 peaks \[[@B49-genes-06-00641]\]. *Nanog* expression is induced in partially reprogrammed cells \[[@B50-genes-06-00641]\], and high *Nanog* levels are associated with a loss of compaction at chromocentres, a feature of pluripotent cells \[[@B36-genes-06-00641]\]. Regions bound by specific TRFs display different dynamics, with OCT4/SOX2, KLF4 and NANOG binding sites losing H3K27me3 early in reprogramming and binding sites for ESRRB and TCFCP2L1 losing H3K27me3 later in reprogramming \[[@B51-genes-06-00641]\]. All these regions maintain a demethylated state in fully reprogrammed iPS cells.

4. Enhancers: Critical Regulatory Elements in Lineage Commitment and Reprogramming
==================================================================================

In both pluripotent and differentiating cells, transcriptional regulatory networks are organized by spatiotemporal contact between distal regulatory elements (often enhancers) and their associated promoters to generate cell type-specific gene expression patterns \[[@B52-genes-06-00641]\]. The coordinated action of critical TRFs binding to specific motif sequences within both promoters and more distal enhancers maintains the ES cell transcriptome \[[@B14-genes-06-00641],[@B53-genes-06-00641],[@B54-genes-06-00641]\]. TRF activity at distal enhancers is critical in modulating gene expression, in guiding cell fate specification during developmental transitions, and in acquiring the iPS cell state during reprogramming \[[@B55-genes-06-00641],[@B56-genes-06-00641]\].

Enhancers are often located at significant distances from the genes they regulate, and function in a position- and orientation-independent manner; as a result they have been difficult to identify, functionally characterize, and link to the genes they regulate. ChIP-Seq studies that investigated OCT4, SOX2 and NANOG binding throughout the genome found that regions of \~1 kb co-bound by all three factors in ES cells exhibited enhancer activity in reporter assays \[[@B14-genes-06-00641]\]. Super-enhancers that cover larger regions (median size 8 kb) and often contain more than one OCT4, SOX2, and NANOG co-bound region, have been proposed to regulate cell identity-associated genes \[[@B54-genes-06-00641],[@B57-genes-06-00641]\]. These proposed CREs were defined either by higher association with the mediator complex or increased levels of H3K27ac \[[@B54-genes-06-00641],[@B57-genes-06-00641]\]. While there is debate as to the function of super-enhancers throughout the genome \[[@B58-genes-06-00641]\], one such region, the *Sox2* Control Region (SCR), has been shown to be essential for *Sox2* transcription and maintenance of the embryonic stem cell phenotype \[[@B59-genes-06-00641],[@B60-genes-06-00641]\]. Deletion of the SCR in ES cells impairs ES cell differentiation to neuroectoderm, revealing the important role this region plays in early lineage commitment \[[@B59-genes-06-00641]\]. Many enhancers are thought or known to be required for lineage commitment ([Table 1](#genes-06-00641-t001){ref-type="table"}). Transcription factors involved in lineage commitment bind to these enhancers and may modulate gene expression in a lineage-specific way \[[@B61-genes-06-00641],[@B62-genes-06-00641],[@B63-genes-06-00641],[@B64-genes-06-00641]\].

genes-06-00641-t001_Table 1

###### 

Enhancers and their predicted or known role in lineage specification.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Name of Enhancer and/or Its Targeted Gene   Relative Enhancer Location                                                                      Predicted or Known Specified Cell Lineage
  ------------------------------------------- ----------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------
  *Pu.1*                                      14 kb upstream of the *Pu.1* promoter                                                           Monocytes \[[@B65-genes-06-00641]\]

  *Mpo*                                       3.2 kb upstream of *Mpo*                                                                        Promyelocytes \[[@B66-genes-06-00641]\]

  *Bmp4*                                      46 kb upstream of *Bmp4* promoter                                                               Mesoderm \[[@B67-genes-06-00641]\]

  SCR, enhancer of *Sox2*                     104--112 kb downstream of *Sox2*                                                                Neuroectoderm \[[@B59-genes-06-00641]\]

  HBE, enhancer of *Nodal*                    3 kb upstream of *Nodal* TSS                                                                    Extra-embryonic precursors \[[@B68-genes-06-00641]\]

  SHF-specific *Isl-1*                        4 kb downstream of *Isl-1*                                                                      Cardiac progenitors \[[@B69-genes-06-00641]\]

  Enhancers of *Pax5*                         5th intron of *Pax5* locus\                                                                     B-lineage lymphocytes\[[@B70-genes-06-00641]\]\
                                              5\' flanking region of *Pax5*                                                                   MHB boundary \[[@B71-genes-06-00641]\]

  *Myf5*                                      48 kb upstream of *Myf5* TSS                                                                    Epaxial muscle progenitors \[[@B72-genes-06-00641],[@B73-genes-06-00641]\]

  *Fn1*                                       12th intron of *Fn1*                                                                            Extra-embryonic endoderm \[[@B74-genes-06-00641]\]

  AHF-specific enhancer of *Mef2c*            16.3 kb downstream of the first untranslated *Mef2c* exon                                       Cardiac progenitors \[[@B75-genes-06-00641]\]

  U2, enhancer of *Sox10*                     47.3 kb upstream of *Sox10*                                                                     Oligodendrocyte precursors \[[@B76-genes-06-00641],[@B77-genes-06-00641]\]

  Ectodermal enhancer of *Pax6*               3.5 kb upstream of *Pax6*                                                                       Corneal lineage \[[@B78-genes-06-00641]\]

  Distal enhancer of *Pax6*                   125 kb downstream of *Pax6*                                                                     α-cells and neural lineage \[[@B79-genes-06-00641],[@B80-genes-06-00641]\]

  Enhancers of *Gata1*                        25 kb upstream, 3.5 kb upstream, and 6 kb downstream of first *Gata1* exon erythroid promoter   Erythroid lineage \[[@B81-genes-06-00641]\]

  B108, enhancer of *Blimp1*                  11 kb downstream of *Blimp1*                                                                    Retinal cells \[[@B82-genes-06-00641]\]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

TSS---transcription start site; AHF---anterior heart field; HBE---highly binding element; SCR---Sox2 control region; SHF---second heart field; MHB---midbrain-hindbrain boundary.

Some transcription factors have pioneer activity, or the ability to access condensed chromatin, alter the accessibility of enhancers, and allow the binding of subsequent factors. Conversely, other transcription factors bind mainly to accessible enhancers and thus require a pre-existing chromatin configuration. The latter is the case for FOX3P, which is required during T-cell lineage specification \[[@B83-genes-06-00641]\]. Some enhancers for genes involved in orchestrating the early events in lineage commitment therefore need to be epigenetically poised for activation, as previously described \[[@B41-genes-06-00641],[@B84-genes-06-00641]\]. These poised enhancers are enriched with H3K4me1 in ES cells and are selectively activated during differentiation whereby they acquire H3K27ac to support the new developmental state \[[@B85-genes-06-00641]\]. For example, the Neuroglycan-C and Neurophilin-2 loci harbor poised enhancers in ES cells that acquire H3K27ac in neural progenitor (NP) cells \[[@B44-genes-06-00641]\].

During the initial phase of somatic cell reprogramming, distal regulatory elements located in closed chromatin are bound by OSK, revealing the pioneer activity of this complex \[[@B86-genes-06-00641]\]. Regulatory elements accessible to OSK despite their closed chromatin state are near genes that are important in the process of reprogramming, such as genes involved in mesenchymal to epithelial transition (MET) \[[@B86-genes-06-00641]\]. Pioneer activity of the OSK complex, however, is impeded at H3K9me3-enriched regions of the genome, which include genes involved in the later stages of reprogramming, such as *Nanog* and *Sox2* \[[@B86-genes-06-00641]\]. A subclass of permissive enhancers in fibroblasts are modified by H3K4me1 and nucleosome depletion, and exhibit DNase I hypersensitivity \[[@B87-genes-06-00641]\]. These permissive enhancers allow binding of ectopically expressed factors regardless of their pioneering potential, and co-ordinate changes to their cognate promoters. For example, ectopically expressed OCT4 binds the *Myod1* enhancer and stimulates acquisition of a bivalent domain at the *Myod1* promoter similar to that observed in ES cells \[[@B87-genes-06-00641]\]. Conversely, binding of MYOD1 to this same enhancer causes the promoter to acquire an active chromatin signature and leads to subsequent activation of *Myod1* transcription. In these examples, binding of transcription factors to distal regulatory elements precedes changes in chromatin state at the associated promoters, displaying the mechanistic importance of CREs in the reprogramming process. Specific enhancers have also been targeted and activated using designer transcription factors to enhance ES cell conversion to iPS cells, further illustrating the importance of these regions in the reprogramming process \[[@B88-genes-06-00641],[@B89-genes-06-00641]\].

5. Genome Architectural Changes during ES Cell Differentiation
==============================================================

As with smaller scale chromatin features, entire chromosomes exhibit specific structural properties dependent upon cell type. The ES cell nucleus has unique features that are associated specifically with pluripotency and are thought to be required for the balance between self-renewal and differentiation. ES cells have been shown to be rich in euchromatin \[[@B90-genes-06-00641]\], perhaps in part due to the abundant expression of proteins involved in chromatin remodeling \[[@B91-genes-06-00641]\]. Coupled with elevated levels of euchromatin, ES cell nuclei display increased global transcription levels \[[@B92-genes-06-00641]\] and approximately twice the total number of sites of nascent transcription, termed transcription factories, compared with differentiated cells \[[@B93-genes-06-00641]\]; however, transcription factory density and diameter are similar between ES and differentiated cells. Although not conducted in pluripotent cells, the application of live-imaging techniques to several primary cell lines has verified the existence of transcription factories in live cells \[[@B94-genes-06-00641],[@B95-genes-06-00641]\]. The observations of open chromatin state and elevated gene expression are consistent with those of highly plastic chromatin displaying more dynamic movements in the ES cell nucleus prior to differentiation \[[@B96-genes-06-00641],[@B97-genes-06-00641]\]. Increased global transcription and chromatin remodeling protein expression were shown to be altered upon differentiation. Furthermore, the differentiation process induces genome compaction, increasing the proportion of heterochromatin in the nucleus \[[@B98-genes-06-00641]\]. The spatial organization of chromosomes within the nucleus has also been demonstrated to be cell type-specific \[[@B99-genes-06-00641]\]. Fluorescence *in situ* hybridization (FISH) experiments have shown that entire chromosomes occupy distinct territories in the nucleus. The relative positions of individual chromosomes display cell type-associated preferences \[[@B5-genes-06-00641],[@B100-genes-06-00641]\]. One well studied differentiation-associated chromosome re-arrangement is the inactivation of one of the two X-chromosomes in female cells. A molecular event that ensures correct expression dosage of X-linked gene products, this inactivation is thought to be achieved by the three-dimensional spreading of *Xist*, which mediates the compaction of one X chromosome through recruitment of the polycomb complex PRC2 as naïve ES cells differentiate toward EpiSC \[[@B101-genes-06-00641]\]. Interestingly, reversal of X chromosome inactivation through the removal of *Xist* and alteration of the epigenome during reprogramming requires a direct reversal of the inactivation process to achieve pluripotency, and can only be brought about through the expression of pluripotency-associated genes \[[@B102-genes-06-00641]\].

Changes in chromosome structure can also be observed by chromosome conformation capture (3C), a molecular technique that captures proximity between chromatin regions through formaldehyde cross-linking and *de novo* ligation of chromatin fragments contained within the same cross-linked chromatin complex \[[@B103-genes-06-00641]\]. Chromosome architecture has been modeled from a high throughput 3C variant, Hi-C, which revealed that the genome resembles a fractal globule structure \[[@B104-genes-06-00641]\] that theoretically allows for dynamic rearrangements without spatial conflicts such as knotting. These Hi-C experiments support other studies' observations that some genes "loop out" of their chromosome territories upon activation \[[@B105-genes-06-00641]\] and contact genes from other chromosomes at transcription compartments \[[@B106-genes-06-00641],[@B107-genes-06-00641]\]. In ES cells, exonic regions are commonly found near the periphery of their respective chromosome territories, perhaps due to the higher global transcriptional activity and increase in the proportion of euchromatin observed in the nucleus \[[@B90-genes-06-00641],[@B108-genes-06-00641]\]. Hi-C has provided a higher resolution analysis of chromatin architecture in ES cells, revealing the aforementioned Mb-scale, self-preferential interacting TAD regions \[[@B6-genes-06-00641]\]. Unlike some other architectural features of the genome in ES cell nuclei, these domain boundaries were found to be largely stable across cell types and species. TAD boundaries are enriched in the architectural protein CTCF, a protein that binds insulator regions \[[@B6-genes-06-00641]\]. TAD domains have also been linked to replication domain boundaries and correlate with the replication timing of euchromatin and heterochromatin in ES cells \[[@B109-genes-06-00641]\]. The conservation in genome organization at the TAD scale suggests that ES cell differentiation does not disturb, or require the reorganization of, TAD boundaries.

6. Dynamics of Chromatin Looping within TADs
============================================

Chromatin loops directly implicated in gene regulation generally reside within TAD boundaries. Many of these smaller scale genome folding events are chromatin interactions that connect enhancers or putative enhancers to TSS. Distances between distal CREs and target gene promoters vary but can be in the Mb range. Studies testing for the presence of putative enhancer-TSS contacts at a single locus level have used the traditional 3C approach previously mentioned \[[@B103-genes-06-00641]\] or the 3C-based variant 4C \[[@B110-genes-06-00641]\]. Interrogation of genome-wide putative enhancer-TSS chromatin loops has involved several genome-wide or high throughput variants of 3C, which include 5C \[[@B111-genes-06-00641]\], ChIA-PET \[[@B112-genes-06-00641]\], Hi-C \[[@B104-genes-06-00641]\], Capture-C \[[@B113-genes-06-00641]\] and Capture Hi-C \[[@B114-genes-06-00641]\].

Both regulatory and constitutive genome-genome contacts appear to be supported by one or more of the following: the aforementioned TAD boundary-associated CTCF, the cohesin complex and the mediator complex. At the loci of several genes integral for ES cell function, most chromatin interacting regions are enriched by binding of the cohesin complex subunit SMC1 or co-binding of SMC1 with either CTCF or mediator \[[@B53-genes-06-00641]\]. Consistent with the critical role of chromatin loops in stem cell maintenance, these three proteins are all necessary for ES cell sustainment \[[@B115-genes-06-00641],[@B116-genes-06-00641]\]. The loop-associated protein list has also been extended to include ZNF143, a human ES cell identity determinant \[[@B117-genes-06-00641]\] and a protein that co-occupies CTCF- and SMC1-bound loop regions in various cancer cell lines \[[@B7-genes-06-00641],[@B118-genes-06-00641],[@B119-genes-06-00641]\]. The murine equivalent ZFP143 is indispensable for *Nanog* regulation and ES cell self-renewal \[[@B120-genes-06-00641]\], which further aligns its function and action mechanism in ES cells to those of the more extensively studied loop-associated proteins. Some combination of these proteins binds the majority of chromatin interaction anchor sites in ES cells, but only a quarter of the anchor sites in NP cells \[[@B53-genes-06-00641]\]. This observation suggests that as yet uncharacterized or undiscovered factors may regulate and support loop formation in a lineage-specific manner.

Less is known regarding the putative role of pluripotency factors in the establishment of ES cell-specific chromatin loops. The enrichment of tissue-specific SMC1 binding at ES cell-specific chromatin interaction sites in either the presence or absence of OCT4, SOX2, and NANOG co-binding initially suggested that pluripotency factors may be dispensable for the loop anchoring mechanism that is mediated by the cohesin complex \[[@B53-genes-06-00641]\]. Other studies, however, demonstrate direct dependencies between loop-associated proteins and pluripotency factors. For instance, ZFP143 recruits OCT4 to the *Nanog* promoter, which is bound by both TRFs in ES cells \[[@B120-genes-06-00641]\]. *Klf4* knockdown reduces both SMC1 binding at the *Oct4* distal enhancer as well as *Oct4* distal enhancer-promoter loop formation in pluripotent stem cells \[[@B121-genes-06-00641]\]. Furthermore, select TRFs have been implicated in working with known loop-associated proteins to re-configure the chromatin architecture of particular loci in different cell types, such as the TFIID complex subunit TAF3 and SALL4 in endoderm lineage commitment \[[@B122-genes-06-00641],[@B123-genes-06-00641]\]. These studies collectively suggest that pluripotency factors may have a role in anchoring the regulatory loops of at least some loci upon cell fate specification.

Studies that interrogate changes in genome folding as ES cells differentiate into cells of disparate lineages have observed instances where chromatin loops can be conserved or can vary across cell types. Both ES cells and NP cells were shown to have overlapping CTCF- and cohesin-bound sites involved in Mb-sized constitutive interactions consistent with TAD boundaries. In contrast, sites co-bound by cohesin and mediator were prevalent in sub-Mb-sized interactions present only in ES cells \[[@B53-genes-06-00641]\]. At the *Olig1/2* locus, for instance, several CTCF- and cohesin-bound loops whose contact sites flank *Olig1* and *Olig2* in the linearized view of the locus are conserved upon ES cell differentiation to NP cells. However, a smaller ES cell-specific looping event enriched in mediator and cohesin binding was detected between a putative ES cell-specific *Olig1* enhancer and its promoter. Differential *trans* chromosomal interactions were also observed between the *Olig1* and *Olig2* promoters and genes implicated in neuronal development in neural stem cells and NP cells \[[@B124-genes-06-00641]\], supporting the link between genome folding patterns and cell identity. It has furthermore been postulated that, in addition to establishing TAD boundaries, constitutive interactions may pre-mark differentiated cell-specific regulatory interactions \[[@B53-genes-06-00641]\]. For instance, the CTCF-, cohesin-, and mediator-enriched SCR region over 100 kb downstream of *Sox2*, loops to the *Sox2* promoter in ES cells, but not in NP cells \[[@B53-genes-06-00641],[@B59-genes-06-00641]\]; however, a more distal region bound by CTCF and cohesin in ES cells contacts the *Sox2* promoter in NP cells and is thought to become a NP cell-specific *Sox2* enhancer \[[@B53-genes-06-00641]\].

The significance of genome folding patterns in determining cell fate is further highlighted by their role in cellular reprogramming. Proper chromatin looping events must be established for successful pluripotency induction in differentiated cells \[[@B125-genes-06-00641]\]. As is the case for ES cells, cohesin and mediator are indispensable for iPS cell enhancer-promoter contacts and self-renewal \[[@B126-genes-06-00641],[@B127-genes-06-00641]\]. Furthermore, regions involved in looping at the *Oct4* and *Nanog* loci are largely shared between ES and iPS cells, but are not observed in fibroblasts \[[@B126-genes-06-00641],[@B127-genes-06-00641]\]. Several studies also promote the idea of enhancer activation occurring prior to gene activation. For instance, pluripotent cell-specific chromatin interactions are established at the *Nanog*, *Lefty1* and *Oct4* loci during the early stages of reprogramming and well in advance of gene expression \[[@B126-genes-06-00641]\]. These results support a reprogramming model in which differentiated cells reacquire an ES cell-specific chromatin architecture that precedes the loop-dependent activation of pluripotency-associated gene expression.

7. Conclusions and Future Directions
====================================

Multiple studies have provided evidence that cell lineage commitment and pluripotency induction depend on the structural and functional contributions of CREs and TRFs to cell transcription programs. A model of chromatin dynamics-mediated expression regulation is emerging in which distal enhancer regions play a central role in cell fate specification and reprogramming ([Figure 1](#genes-06-00641-f001){ref-type="fig"}). Nevertheless, the precise molecular mechanisms by which these elements carry out their regulatory roles and act at a distance with specificity have yet to be determined. Genome-wide dynamic profiling of TRFs and histone modifications throughout the reprogramming process provide a starting point for the identification of putative regulatory regions that drive pluripotency acquisition and maintenance. However, transcription factor regulatory networks are highly interconnected; therefore, the contributions of each transcription factor to the regulation of cell state-maintaining genes and the specific sequence motifs through which these factors function can be difficult to elucidate. Additionally, the identification of all critical transcription factor complex members, as well as the dosage-dependent effects of each factor on the pluripotency transcriptional program, are questions that require further investigation.

In the case of CREs, probing of ES and iPS cell *cis* regulomes by genome-wide chromatin loop-detecting methods has provided a repertoire of putative cell-specific CREs and the gene promoters they contact. The vast majority of these data, however, have emerged from studies of whole cell populations. Additional employment of single cell 3C variants, such as the single cell version of the Hi-C method \[[@B128-genes-06-00641]\] may provide a more accurate representation of structural chromatin dynamics. Furthermore, the mechanisms through which individual CREs select a cell's particular lineage commitment pathway are largely unknown. What contributions individual CREs make during the various stages of differentiation into each cell type throughout organism development also remain to be determined. These questions can be more efficiently addressed with the advent of CRISPR-Cas9-based genome editing, CRISPR interference/activation and Cas9-mediated epigenome control \[[@B129-genes-06-00641],[@B130-genes-06-00641],[@B131-genes-06-00641],[@B132-genes-06-00641],[@B133-genes-06-00641]\]. Use of these technologies, coupled with various high-resolution and single cell chromatin loop-detecting assays, will provide a better understanding of the players involved in transcriptional regulatory mechanisms.

![Changes in chromatin accessibility and modification drive the processes of differentiation and reprogramming. Pluripotent cells possess less compact chromatin compared to differentiated cells (light and medium intensity blue, respectively) and lack the compact chromocentres (dark blue) present in differentiated cells (top). The more open chromatin configuration in ES and iPS cells creates less nucleosome compaction (bottom left); as a result, nucleosomes are found in smaller clutches in ES and iPS cells as indicated by two clutches of four and seven nucleosomes, respectively. On the right the more compact chromatin of differentiated cells displays a greater overall density of nucleosomes and larger clutches of nucleosomes. Despite this chromatin compaction in differentiated cells, the reprogramming factors, OSKM, can access enhancer regions in condensed chromatin (blue bar), initiate chromatin remodeling at the enhancer, lead to chromatin remodeling at the gene (black bar) TSS, and eventually activate target genes as cells acquire the iPS state. This process converts the heterochromatic regions in fibroblasts marked by H4K27me3 to euchromatic regions in the iPS cells marked by H3K27ac and H3K4me1 or H3K4me3 at the enhancer and promoter respectively. CTCF and cohesin are found at both tissue-specific and constitutive chromatin loops. The coactivators (p300 and the mediator complex) are found at tissue-specific enhancer-promoter chromatin loops and are thought to bridge transcription factors at distal enhancers to the RNA polymerase II complex at the gene TSS.](genes-06-00641-g001){#genes-06-00641-f001}

The need for chromatin dynamics-focused studies is highlighted by the fact that gained knowledge can give rise to new avenues of research with potential for therapeutic developments. For instance, the induction of an artificial chromatin loop between embryonic fetal *globin* and the well-characterized *globin* locus control region (LCR) in both mouse and human erythroid cells has emerged as the basis for potential mitigation of sickle cell anemia and β-thalassemia \[[@B134-genes-06-00641]\]. This seminal paper, however, has come about as a result of a thorough (and still ongoing) study of the individual molecular players involved in the epigenomic state, genome folding patterns, and transcription activation events at the β*-globin* locus. This demonstrates the need to better characterize the regulatory mechanisms of enhancers at other loci in different cell types. Indeed, similar experiments have enormous potential in the contexts of reprogramming and stem cell therapies. Impediments to the use of reprogrammed cells in a clinical context, including low reprogramming efficiency, extensive required time span, and uncertainty of acquiring the desired differentiated cell state may arise at least in part due to the inability of reprogramming factors to efficiently access and remodel specific enhancers, as described above. Using enhancer activation at these resistant enhancers in pluripotency-induced cells could therefore greatly improve the efficiency of the reprogramming process.
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